An overview on peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan

Angiology

Volumn 53, Issue 5, 2002, Pages 529-537

  Tseng, Chin Hsiao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; TAP WATER;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; BLACKFOOT DISEASE; CELL PROLIFERATION; CHILD; CLINICAL FEATURE; DIABETES MELLITUS; ENDEMIC DISEASE; ENDOTHELIUM INJURY; HUMAN; HYPERCOAGULABILITY; HYPERKERATOSIS; HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MICROCIRCULATION; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PREVALENCE; SKIN CANCER; SMOOTH MUSCLE; TAIWAN;

EID: 0036741440     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970205300505     Document Type: Article

References (54)

1. Wu HY, Chen KP, Tseng WP, et al: Epidemiologic studies on blackfoot disease. I. Prevalence and incidence of the disease by age, sex, year, occupation and geographical distribution. Memoirs College Med Natl Taiwan Univ 7:33-50, 1961.
2. Tseng WP, Chen WY, Sung JL, et al: A clinical study of blackfoot disease in Taiwan, an endemic peripheral vascular disease. Memoirs College Med Natl Taiwan Univ 7:1-18, 1961.
3. Lu FJ, Tsai MH, Ling KH: Studies on fluorescent compounds in drinking water of areas endemic for blackfoot disease. 3. Isolation and identification of fluorescent compounds. J Formosan Med Assoc 77:68-76, 1978.
4. Yeh SJ, Wu CT, Yang CY: Neutron activated analysis of blackfoot disease related specimens: (I) Trace elements in serum, urine, hair and nail samples. Blackfoot Dis Res Rep 16:1-21, 1983.
5. Yeh SJ, Yang MH: Preliminary report on trace foot disease endemic area and in biopsy samples of blackfoot disease patients. Blackfoot Dis Res Rep 8:22-28, 1980.
6. Tseng WP: Blackfoot disease in 0Taiwan: A 30-year follow-up study. Angiology 40:547-558, 1989.
7. Tseng CH, Chong CK, Chen CJ, et al: Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 120:125-133, 1996.
8. Tseng CH, Chong CK, Chen CJ, et al: Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. Angiology 48:321-335, 1997.
9. Chi IC, Blackwell RA: A controlled retrospective study of blackfoot disease, an endemic peripheral gangrene disease in Taiwan. Am J Epidemiol 88:7-24, 1968.
10. Yeh S, How SW: A pathological study on the blackfoot disease in Taiwan. Reports, Institute of Pathology, National Taiwan University 14:25-73, 1963.
11. Wu HY, Sun CC, Chen CS, et al: Epidemiologic research on blackfoot disease (in Chinese). Blackfoot Dis Res Rep 30:1-102, 1988.
12. Chen KP, Wu HY, Wu TC: Epidemiologic studies on blackfoot disease in Taiwan: III. Physicochemical characteristics of drinking water in endemic blackfoot disease areas. Memoirs College Med Natl Taiwan Univ 8:115-129, 1962.
13. Kuo TL: Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Reports of Institute of Pathology, Taipei, Taiwan: National Taiwan University College of Medicine 20:7-13, 1964.
14. Smith AH, Hopenhayn-Rich C, Bates MN, et al: Cancer risks from arsenic in drinking water. Environ Health Prospect 97:259-267, 1992.
15. Lo MC, Hsen YC, Lin BK: Arsenic content of underground water in Taiwan: Second report. Taichung, Taiwan: Taiwan Provincial Institute of Environmental Sanitation. 1977, pp 1-21.
16. Lo MC: The arsenic content of farm products and fishes in areas where high arsenic well water was used for agriculture and pisciculture. Blackfoot Dis Res Rep 6:28-46, 1978.
17. Blackwell RQ: Estimated total arsenic ingested by residents in the endemic blackfoot area. J Formosan Med Assoc 60:1143-1144, 1961.
18. Agency for toxic substances and disease registry (ATSDR): Toxicological profile for arsenic. U.S. Environmental Protection Agency (EPA). U.S.A. 1989, p 5.
19. Tseng WP, Chu HM, How SW, et al: Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40:453-463, 1968.
20. Wang JD, Hu FC, Chiang CY, et al: Occurrence of blackfoot disease before and after tap water implementation (in Chinese). Blackfoot Dis Res Rep 18:21-35, 1983.
21. Tseng CH, Chen CJ, Lin BJ, et al: Abnormal response of ankle pressure after exercise in seemingly normal subjects living in blackfoot disease-hyperendemic villages in Taiwan. Vasc Surg 28:607-617, 1994.
22. Tseng CH, Tai TY, Lin BJ, et al: Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot disease-hyperendemic villages in Taiwan. Int J Microcirc 15:21-27, 1995.
23. Waalkes MP, Fox DA, States JC, et al: Metals and disorders of cell accumulation: Modulation of apoptosis and cell proliferation. Toxicol Sci 56:255-261, 2000.
24. 3) on cultured human umbilical vein endothelial cells. J Dermatol 17:599-608, 1990.
25. Shen MC, Tseng WP, Chen KS: Increased blood level of platelet aggregates and coagulating factors in blackfoot disease patients (in Chinese). Blackfoot Dis Res Rep 15:20-28, 1983.
26. Lynn S, Gurr JR, Lai HT, et al: NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res 86:514-519, 2000.
27. Akao Y, Yamada H, Nakagawa Y: Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma 37:53-63, 2000
28. Lilienfeld DE: Arsenic, geographical isolates, environmental epidemiology and arteriosclerosis. Arteriosclerosis 8:449-451, 1988.
29. Mahaffey KR, Capar SG, Gladen BC, et al: Concurrent exposure to lead, cadmium, and arsenic. Effects on toxicity and tissue metal concentrations in the rat. J Lab Clin Med 98:463-481, 1981.
30. Levander OA: Metabolic interrelationships between arsenic and selenium. Environ Health Perspect 19:159-164, 1977.
31. Pershagen G, Wall S, Taube A, et al: On the interaction between occupational arsenic exposure and smoking and its relationship to lung cancer. Scand J Work Environ Health 7:302-309, 1981.
32. Pershagen G, Nordberg G, Bjorkland NE: Carcinomas of the respiratory tract in hamsters given arsenic trioxide and/or benzo-a-pyrene by the pulmonary route. Environ Res 37:425-432, 1984.
33. Engel RR, Hopenhayn-Rich C, Receveur O, et al: Vascular effects of chronic arsenic exposure: A review. Epidemiol Rev 16:184-209, 1994.
34. Chen CJ, Hsueh YM, Lai MS, et al: Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53-60, 1995.
35. Tseng CH, Tai TY, Chong CK, et al: Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: A cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect 108:847-851, 2000.
36. Tseng CH, Chong CK, Heng LT, et al: The incidence of diabetes mellitus in Taiwan. Diabetes Res Clin Pract 50(suppl 2):S61-S64, 2000.
37. Hansen ES: Shared risk factors for cancer and atherosclerosis: A review of epidemiological evidence. Mutat Res 239:163-179, 1990.
38. Benditt EP, Benditt JM: Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 70:1753-1756, 1973.
39. Hatzistamou J, Kiaris H, Ergazaki M, et al: Loss of heterozygosity and microsatellite instability in human atherosclerotic plaque. Biochem Biophys Res Commun 255:186-190, 1996.
40. Chen CJ, Lin LJ: Human carcinogenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In: Arsenic in the Environment, Part II: Human Health and Ecosystem Effects, ed. by Nriagu JO. New York: John Wiley & Sons, Inc, 1994, pp 109-131.
41. Elbirt KK, Whitmarsh AJ, Davis RJ, et al: Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells: Role of mitogen-activated protein kinases. J Biol Chem 273:8922-8932, 1998.
42. Masuya Y, Hioki K, Tokunaga R, et al: Involvement of the tyrosine phosphorylation pathway in induction of human heme oxygenase-1 by hemin, sodium arsenite, and cadmium chloride. J Biochem 124:628-633, 1998.
43. Lopez S, Miyashita Y, Simons SS Jr: Structurally based, selective interaction of arsenite with steroid receptor. J Biol Chem 165:16039-16042, 1990.
44. Thomas MJ: Physiological aspects of low-density lipoprotein oxidation. Curr Opin Lipidol 11:297-301, 2000.
45. Thurberg BL, Collins T: The nuclear factor-κB/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 9:387-396, 1998.
46. Rao GN, Lassegue B, Griendling KK, et al: Hydrogen peroxide stimulates transcription of c-jun in vascular smooth muscle cells: Role of arachidonic acid. Oncogene 8:2759-2764, 1993.
47. Nordenson I, Beckman L: Is the genotoxic effect of arsenic mediated by oxygen free radicals? Hum Hered 41:71-73, 1991.
48. Galle J, Heermeier K, Wanner C: Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int 71(suppl):S62-S65, 1999.
49. Houtman JP: Trace elements and cardiovascular diseases. J Cardiovasc Risk 3:18-25, 1996.
50. Wu G, Meininger CJ: Arginine nutrition and cardiovascular function. J Nutr 130:2626-2629, 2000.
51. Faggiotto A, Poli A, Catapano AL: Antioxidants and coronary artery disease. Curr Opin Lipidol 9:541-549, 1998.
52. Hsueh YM, Wu WL, Huang YL, et al: Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis 141:249-257, 1998.
53. Hunder G, Nguyen PT, Schümann K, et al: Influence of inorganic and organic arsenicals on intestinal transfer of nutrients. Res Commun Chem Pathol Pharmacol 80:83-92, 1993.
54. Tseng CH: Chronic arsenic intoxication in Asia: Current perspectives. J Intern Med Taiwan 10:224-229, 1999.